{"analyses":[{"ciLowerLimit":"2.855","ciPctValue":"95","ciUpperLimit":"8.075","estimateComment":"Afatinib 40 mg-Pemetrexed/Cisplatin Chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"4.802","statisticalComment":"Logistic regression stratified for EGFR mutation group and race.","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.8","upperLimit":"63.0","value":"56.5"},{"groupId":"OG001","lowerLimit":"15.3","upperLimit":"31.3","value":"22.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"OR was defined as Complete Response (CR) or Partial Response (PR). Assessed by central independent review according to RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"OG001","title":"Pemetrexed/Cisplatin Chemotherapy"}],"paramType":"NUMBER","populationDescription":"RS.","reportingStatus":"POSTED","timeFrame":"Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression","title":"Percentage of Patients With Objective Response (OR)","type":"SECONDARY","unitOfMeasure":"Percentage of patients with OR."}